These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 17388923)

  • 1. An unusual terminal hair growth on the nose tip associated with gefitinib therapy.
    Kim SY; Choi HJ; Park HJ; Lee JY; Cho BK
    Br J Dermatol; 2007 May; 156(5):1087-8. PubMed ID: 17388923
    [No Abstract]   [Full Text] [Related]  

  • 2. Facial hypertrichosis and trichomegaly developing in patients treated with the epidermal growth factor receptor inhibitor erlotinib.
    Vergou T; Stratigos AJ; Karapanagiotou EM; Matekovits AE; Dilana KD; Tsimboukis S; Antoniou C; Chasapi V; Syrigos KN
    J Am Acad Dermatol; 2010 Aug; 63(2):e56-8. PubMed ID: 20633793
    [No Abstract]   [Full Text] [Related]  

  • 3. Toxicity manifesting as cosmetic hair alterations during erlotinib treatment.
    Kudo K; Fujiwara K; Tsushima M; Mizuta M; Matsuo K; Yonei T; Sato T
    Acta Oncol; 2011 Jan; 50(1):146-8. PubMed ID: 20843170
    [No Abstract]   [Full Text] [Related]  

  • 4. A case of trichomegaly of the eyelashes and facial hypertrichosis induced by erlotinib (Tarceva).
    Márquez G; Herrera-Acosta E; Vidal I; Galvany L; Iglesias M; Umbert P
    Int J Dermatol; 2009 Jan; 48(1):97-8. PubMed ID: 19126063
    [No Abstract]   [Full Text] [Related]  

  • 5. Gastric perforation secondary to regression of lung adenocarcinoma after gefitinib treatment.
    Chung WP; Song HL; Ho CL; Chiu NT; Su WC
    J Clin Oncol; 2013 Jan; 31(1):e6-8. PubMed ID: 23169516
    [No Abstract]   [Full Text] [Related]  

  • 6. Hair growth after gefitinib treatment.
    Lee LW; Burt PA
    Clin Oncol (R Coll Radiol); 2005 Sep; 17(6):492-3. PubMed ID: 16149296
    [No Abstract]   [Full Text] [Related]  

  • 7. Persistent hair growth during treatment with the EGFR inhibitor erlotinib.
    Alexandrescu DT; Kauffman CL; Dasanu CA
    Dermatol Online J; 2009 Mar; 15(3):4. PubMed ID: 19379648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe acute interstitial pnuemonia and gefitinib.
    Sumpter K; Harper-Wynne C; O'Brien M; Congleton J
    Lung Cancer; 2004 Mar; 43(3):367-8. PubMed ID: 15165098
    [No Abstract]   [Full Text] [Related]  

  • 9. APL during gefitinib treatment for non-small-cell lung cancer.
    Uchida A; Matsuo K; Tanimoto M
    N Engl J Med; 2005 Feb; 352(8):843. PubMed ID: 15728826
    [No Abstract]   [Full Text] [Related]  

  • 10. Trichomegaly induced by erlotinib.
    Papadopoulos R; Chasapi V; Bachariou A
    Orbit; 2008; 27(4):329-30. PubMed ID: 18716976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sudden onset of interstitial lung disease induced by gefitinib in a lung cancer patient with multiple drug allergy.
    Aoe K; Hiraki A; Murakami T; Maeda T; Umemori Y; Katayama H; Eda R; Takeyama H
    Anticancer Res; 2005; 25(1B):415-8. PubMed ID: 15816604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pneumatosis cystoides intestinalis after gefitinib therapy for pulmonary adenocarcinoma.
    Iwasaku M; Yoshioka H; Korogi Y; Kunimasa K; Nishiyama A; Nagai H; Ishida T
    J Thorac Oncol; 2012 Jan; 7(1):257. PubMed ID: 22173663
    [No Abstract]   [Full Text] [Related]  

  • 13. Acquired trichomegaly and symptomatic external ocular changes in patients receiving epidermal growth factor receptor inhibitors: case reports and a review of literature.
    Zhang G; Basti S; Jampol LM
    Cornea; 2007 Aug; 26(7):858-60. PubMed ID: 17667622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain.
    Wu C; Li YL; Wang ZM; Li Z; Zhang TX; Wei Z
    Lung Cancer; 2007 Sep; 57(3):359-64. PubMed ID: 17434236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib.
    Takano T; Ohe Y; Kusumoto M; Tateishi U; Yamamoto S; Nokihara H; Yamamoto N; Sekine I; Kunitoh H; Tamura T; Kodama T; Saijo N
    Lung Cancer; 2004 Jul; 45(1):93-104. PubMed ID: 15196739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib.
    Graves JE; Jones BF; Lind AC; Heffernan MP
    J Am Acad Dermatol; 2006 Aug; 55(2):349-53. PubMed ID: 16844529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers.
    Lee DH; Han JY; Lee HG; Lee JJ; Lee EK; Kim HY; Kim HK; Hong EK; Lee JS
    Clin Cancer Res; 2005 Apr; 11(8):3032-7. PubMed ID: 15837758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of gefitinib as a first-line therapy in elderly patients with pulmonary adenocarcinoma: West Japan Thoracic Oncology Group Study 0402.
    Kobayashi M; Matsui K; Katakami N; Takeda K; Moriyama A; Iwamoto Y; Takada M; Yoshioka H; Sueoka-Aragane N; Nakagawa K;
    Jpn J Clin Oncol; 2011 Aug; 41(8):948-52. PubMed ID: 21715363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The characteristics and failure pattern of gefitinib responders with postoperative recurrence of pulmonary adenocarcinoma.
    Shoji F; Yano T; Yoshino I; Mori D; Yamasaki F; Kohno H; Maehara Y
    Eur J Surg Oncol; 2008 Jan; 34(1):89-93. PubMed ID: 17449217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential efficacy of gefitinib across age groups in treatment of advanced lung adenocarcinoma.
    Wang H; Zhang G; Li P; Yan X; Wang Q; Zhu H; Qi G; Fan Q; Ma Z
    Pharmazie; 2012 Jan; 67(1):80-5. PubMed ID: 22393836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.